Delcath Systems share price today

(DCTH)

Delcath Systems share price is $11.34 & ₹966.15 as on 25 Dec 2024, 2.30 'hrs' IST

$11.34

▲

-0.1

(-0.87%)

Market is closed - opens 8 PM, 26 Dec 2024

View live Delcath Systems share price in Dollar and Rupees. Guide to invest in Delcath Systems from India. Also see the sentimental analysis on Indian investors investing in Delcath Systems. Get details on the Indian mutual funds that are investing in Delcath Systems. Get Analyst recommendations and forecasts along with all the Delcath Systems's financials.

Delcath Systems share price movements

Today's Low: $11.13
Today's High: $11.57
$11.34
1.89%
Downside
Day's Volatility :3.84%
Upside
1.98%
52 Weeks Low: $3.70
52 Weeks High: $13.30
$11.34
67.37%
Downside
52 Weeks Volatility :72.18%
Upside
14.74%

Delcath Systems Returns

Period	Delcath Systems Inc	Index (Russel 2000)
3 Months	27.85%	0.0%
6 Months	37.79%	0.0%
1 Year	179.31%	0.0%
3 Years	40.35%	-21.1%

Delcath Systems Key Statistics

in dollars & INR

Previous Close	$11.44
Open	$11.4
Today's High	$11.5694
Today's Low	$11.1256
Market Capitalization	$365.8M
Today's Volume	$113.3K
52 Week High	$13.3011
52 Week Low	$3.7
Revenue TTM	$11.9M
EBITDA	$-35.9M
Earnings Per Share (EPS)	$-1.17
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-478.59%

How to invest in Delcath Systems from India?

It is very easy for Indian residents to invest directly in Delcath Systems from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Delcath Systems stock in both Indian Rupees (INR) and US Dollars (USD). Search for Delcath Systems or DCTH on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Delcath Systems or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Delcath Systems shares which would translate to 0.075 fractional shares of Delcath Systems as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Delcath Systems, in just a few clicks!

Returns in Delcath Systems for Indian investors in Rupees

Investment Value

₹1,00,000

Delcath Systems investment value today

Current value as on today

₹2,81,549

Returns

₹1,81,549

(+181.55%)

Returns from Delcath Systems Stock

₹1,79,310 (+179.31%)

Dollar Returns

₹2,239 (+2.24%)

Indian investors sentiment towards Delcath Systems

67%

Period: Sep 26, 2024 to Dec 25, 2024. Change in 30 Days versus previous period

Search volume for Delcath Systems on INDmoney from India has grown in the last 30 days as on Dec 26, 2024. 67% more investors are searching Delcath Systems in the last 30 days versus the previous period.

Global Institutional Holdings in Delcath Systems

Rosalind Advisors, Inc.
8.29%
AIGH Capital Management, LLC
5.57%
Vanguard Group Inc
3.47%
Vivo Capital, LLC
3.12%
Essex Investment Management Company, LLC
1.05%
Renaissance Technologies Corp
0.98%

Analyst Recommendation on Delcath Systems

Buy

90%Buy

9%Hold

0%Sell

Based on 11 Wall street analysts offering stock ratings for Delcath Systems(by analysts ranked 0 to 5 stars)

Based on 11 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Delcath Systems

What analysts predicted

Upside of 88.12%

Current:

$11.34

Target:

$21.33

Insights on Delcath Systems

Price Movement
In the last 1 year, DCTH stock has moved up by 188.5%
Increasing Revenue
Revenue is up for the last 5 quarters, 434.0K → 9.56M (in $), with an average increase of 45.2% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -13.74M → 1.86M (in $), with an average increase of 837.2% per quarter
DCTH vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 113.2% return, outperforming this stock by 79.0%

Delcath Systems Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$3.4M	↑ 25.49%
Net Income	$-19.2M	↓ 57.4%
Net Profit Margin	-564.19%	↑ 1097.58%

	FY19	Y/Y Change
Revenue	$1.6M	↓ 53.62%
Net Income	$-13.6M	↓ 29.11%
Net Profit Margin	-862.47%	↓ 298.28%

	FY20	Y/Y Change
Revenue	$1.6M	↑ 4.18%
Net Income	$-24.5M	↑ 79.68%
Net Profit Margin	-1.5K%	↓ 625.08%

	FY21	Y/Y Change
Revenue	$3.6M	↑ 115.98%
Net Income	$-26.8M	↑ 9.28%
Net Profit Margin	-752.66%	↑ 734.89%

	FY22	Y/Y Change
Revenue	$2.7M	↓ 23.52%
Net Income	$-39.2M	↑ 46.37%
Net Profit Margin	-1.4K%	↓ 687.69%

	FY23	Y/Y Change
Revenue	$2.1M	↓ 24.05%
Net Income	$-47.7M	↑ 21.74%
Net Profit Margin	-2.3K%	↓ 868.51%

	Q2 FY23	Q/Q Change
Revenue	$495.0K	↓ 17.09%
Net Income	$-7.2M	↓ 30.5%
Net Profit Margin	-1.5K%	↑ 280.9%

	Q3 FY23	Q/Q Change
Revenue	$434.0K	↓ 12.32%
Net Income	$-20.3M	↑ 182.42%
Net Profit Margin	-4.7K%	↓ 3231.69%

	Q4 FY23	Q/Q Change
Revenue	$539.0K	↑ 24.19%
Net Income	$-11.1M	↓ 45.25%
Net Profit Margin	-2.1K%	↑ 2620.59%

	Q1 FY24	Q/Q Change
Revenue	$3.1M	↑ 482.37%
Net Income	$-11.1M	↓ 0.22%
Net Profit Margin	-353.97%	↑ 1712.08%

	Q2 FY24	Q/Q Change
Revenue	$7.8M	↑ 147.4%
Net Income	$-13.7M	↑ 23.67%
Net Profit Margin	-176.94%	↑ 177.03%

	Q3 FY24	Q/Q Change
Revenue	$9.6M	↑ 23.1%
Net Income	$1.9M	↓ 113.57%
Net Profit Margin	19.5%	↑ 196.44%

	FY18	Y/Y Change
Profit	$2.4M	↑ 19.07%

	FY19	Y/Y Change
Profit	$861.0K	↓ 64.1%

	FY20	Y/Y Change
Profit	$1.0M	↑ 16.84%

	FY21	Y/Y Change
Profit	$2.9M	↑ 186.68%

	FY22	Y/Y Change
Profit	$2.0M	↓ 29.51%

	FY23	Y/Y Change
Profit	$1.4M	↓ 29.66%

	Q2 FY23	Q/Q Change
Profit	$345.0K	↓ 17.07%

	Q3 FY23	Q/Q Change
Profit	$301.0K	↓ 12.75%

	Q4 FY23	Q/Q Change
Profit	$327.0K	↑ 8.64%

	Q1 FY24	Q/Q Change
Profit	$2.2M	↑ 583.79%

	Q2 FY24	Q/Q Change
Profit	$6.2M	↑ 179.38%

	Q3 FY24	Q/Q Change
Profit	$9.6M	↑ 53.03%

	FY18	Y/Y Change
Operating Cash Flow	$-14.7M	↓ 4.33%
Investing Cash Flow	$-76.0K	↓ 85.5%
Financing Cash Flow	$13.2M	↓ 14.3%

	FY19	Y/Y Change
Operating Cash Flow	$-23.7M	↑ 60.81%
Investing Cash Flow	$-24.0K	↓ 68.42%
Financing Cash Flow	$30.3M	↑ 128.96%

	FY20	Y/Y Change
Operating Cash Flow	$-22.9M	↓ 3.47%
Investing Cash Flow	$-782.0K	↑ 3158.33%
Financing Cash Flow	$42.4M	↑ 39.76%

	FY21	Y/Y Change
Operating Cash Flow	$-22.6M	↓ 1.15%
Investing Cash Flow	$-143.0K	↓ 81.71%
Financing Cash Flow	$20.8M	↓ 50.84%

	FY22	Y/Y Change
Operating Cash Flow	$-25.0M	↑ 10.38%
Investing Cash Flow	$-209.0K	↑ 46.15%
Financing Cash Flow	$10.1M	↓ 51.29%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-9.6M	↑ 126.27%
Investing Cash Flow	$-40.0K	↑ 0.0%
Financing Cash Flow	$7.0K	↓ 99.96%

Delcath Systems Technicals Summary

Sell

Neutral

Buy

Delcath Systems is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Delcath Systems Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Delcath Systems Inc	6.48%	37.79%	179.31%	40.35%	48.04%
Stryker Corporation	-4.86%	8.88%	24.0%	37.11%	77.64%
Boston Scientific Corp.	0.95%	18.27%	62.57%	111.2%	102.42%
Edwards Lifesciences Corp.	5.35%	-19.24%	-1.09%	-42.27%	-2.7%
Abbott Laboratories	-2.71%	9.66%	4.53%	-18.87%	32.21%
Medtronic Plc	-4.83%	2.79%	-1.07%	-21.92%	-27.8%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Delcath Systems Inc	NA	NA	NA	-0.78	-4.79	-0.82	NA	0.69
Stryker Corporation	39.7	39.7	2.56	12.06	0.19	0.07	0.01	52.86
Boston Scientific Corp.	75.26	75.26	1.65	2.46	0.09	0.05	NA	14.05
Edwards Lifesciences Corp.	29.1	29.1	6.92	2.55	0.19	0.11	NA	16.18
Abbott Laboratories	34.88	34.88	2.22	4.68	0.15	0.06	0.02	22.94
Medtronic Plc	24.94	24.94	1.49	5.2	0.08	0.04	0.03	38.29

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Delcath Systems Inc	Buy	$365.8M	48.04%	NA	0.0%
Stryker Corporation	Buy	$141.3B	77.64%	39.7	16.34%
Boston Scientific Corp.	Buy	$134.2B	102.42%	75.26	11.26%
Edwards Lifesciences Corp.	Buy	$44.5B	-2.7%	29.1	65.86%
Abbott Laboratories	Buy	$199.0B	32.21%	34.88	13.99%
Medtronic Plc	Buy	$104.6B	-27.8%	24.94	12.06%

About Delcath Systems

delcath systems, inc. (nasdaq- dcth) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. our proprietary product---melphalan hydrochloride for injection for use with the delcath hepatic delivery system (melphalan/hds)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. delcath is in late-stage clinical development in the united states with initial commercial activities in europe, where the melphalan/hds is marketed as a ce marked device under the trade name delcath hepatic chemosat® delivery system for melphalan (chemosat). our commercial strategy for chemosat is to steadily grow clinical adoption in major european markets and utilize physician experience to support appeals for reimbursement. since launch over 250 chemosat treatments have been performed at over 20 leading european cancer centers. in 2016, we launched our focus pivotal study in hepatic dominant ocular

Organization	Delcath Systems
Employees	76
CEO	Mr. Gerard J. Michel MBA, MS
Industry	Medical Specialties

Management People of Delcath Systems

Name	Title
Mr. Gerard J. Michel MBA, MS	CEO & Director
Ms. Sandra Pennell	Senior VP of Finance and Principal Financial & Accounting Officer
Dr. Martha S. Rook Ph.D.	Chief Operating Officer
Mr. David Hoffman	General Counsel, Corporate Secretary & Chief Compliance Officer
Dr. Johnny John M.D.	Senior Vice President of Clinical Operations & Medical Affairs
Dr. Vojislav Vukovic M.D., M.Sc., Ph.D.	Chief Medical Officer

Important FAQs about investing in Delcath Systems from India :

What is Delcath Systems share price today?

Delcath Systems share price today stands at $11.34, Open: $11.40 ; Previous Close: $11.44 ; High: $11.57 ; Low: $11.13 ; 52 Week High: $13.30 ; 52 Week Low: $3.70. The stock opens at $11.40, after a previous close of $11.44. The stock reached a daily high of $11.57 and a low of $11.13, with a 52-week high of $13.30 and a 52-week low of $3.70.

Can Indians buy Delcath Systems shares?

Yes, Indians can invest in the Delcath Systems (DCTH) from India.

With INDmoney, you can buy Delcath Systems at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Delcath Systems at zero transaction cost.

How can I buy Delcath Systems shares from India?

It is very easy to buy Delcath Systems from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Delcath Systems be purchased?

Yes, you can buy fractional shares of Delcath Systems with INDmoney app.

What are the documents required to start investing in Delcath Systems stocks?

To start investing in Delcath Systems, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.